Durable cure of mucormycosis involving allograft and native lungs.
Among the spectrum of fungi causing disease in lung allograft recipients, fungi in the order Mucorales represent uncommon pathogens. Lung transplant patients, however, often possess more than one risk factor for development of life-threatening mucormycosis. We describe a unique case of pulmonary mucormycosis involving both the allograft and the native lungs, in a single lung transplant recipient with steroid-induced diabetes. Extended intravenous amphotericin B and oral fluconazole therapy, reduction of immunosuppression, and blood glucose control achieved a durable cure without the need for surgical intervention. Early diagnosis with prompt initiation of multiagent antifungal therapy, prolonged continuation of antifungal therapies, and amelioration of contributing conditions are important elements of the treatment strategy that led to successful resolution of the infection.
Zander
D S
DS
Department of Pathology, University of Florida College of Medicine, and Veterans Affairs Medical Center, Gainesville, Florida, USA. zander@pathology.ufl.edu
Cicale
M J
MJ
Mergo
P
P
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D004333:Drug Administration Routes; D004359:Drug Therapy, Combination; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D016040:Lung Transplantation / Q000009:adverse effects*; D009091:Mucormycosis / Q000188:drug therapy*; D014184:Transplantation, Homologous
D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D000666:Amphotericin B; D015725:Fluconazole